Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-101 in Total Knee Arthroplasty (SPARK)
NCT05260008Phase 2Terminated
- Sponsor
- Allay Therapeutics
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ATX101 in acute postoperative pain (3 arms), sponsored by Allay Therapeutics. Primary endpoint: Area Under the Curve for the Numeric Rating Scale at Rest of Pain Intensity. Started Jun 2022; status: terminated.
02
Drugs
ATX101
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on NCT05260008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260008.